Peru also shows successful treatment with Ivermectin

Ivermectin is a highly controversial drug originally developed to treat malaria but is now used with great success for the prophylaxis and early treatment of Covid. In large-scale applications such as in India with hundreds of millions of people, it has already proven to be very effective.

Eine new published in PubMed study demonstrates the effectiveness in Meta an analyzes of existing studies, as well as hand experience with an also extensively over large areas in Peru. The study is titled: " Ivermectin: A Versatile Nobel Prize-winning drug with proven effectiveness against a new global scourge, COVID-19."

In 2015, the Nobel Committee on Physiology or Medicine, with its only award for the treatment of infectious diseases in six decades, recognized the discovery of ivermectin (IVM), a versatile drug used to treat some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments.

Clinical evidence for the effectiveness of ivermectin

Six of seven meta-analyses of IVM treatment RCTs published in 2021 found remarkable reductions in COVID-19 deaths, with an average relative risk of death of 31% compared to controls. The seventh of these meta-analyzes in their first version found no indication of the effectiveness of the IVM and reported a risk reduction of 1.11 for the IVM treatment compared to the controls.

This result was retained even after a revised version changed this value to 0.37 and the fatalities incorrectly reported in one study were corrected by treatment and controls. However, this does not prevent the mainstream media and the media appearing in Germany for doctors from citing the proven incorrect result in order to raise awareness against the drug. Because the corona measures and the approval of the vaccines stand and fall with the alleged lack of effective treatments.

One objection raised in 2021 to the clinical evidence summarized above for the effectiveness of IVM treatment for COVID-19 was that none of these RCTs had been published in recognized peer-reviewed scientific journals. That is no longer true.

Another objection that has been raised against the RCT evidence for the effectiveness of IVM, was that the study populations small to be . It is well known, however, that potent drugs statistically significant results already achieved with smaller sample sizes, while necessary for minimally effective medications larger study populations.

Recently, Dr. Satoshi Omura, Nobel Laureate for the Discovery of IVM, and his colleagues conducted a comprehensive review of the clinical activity of IVM against COVID-19 and concluded that the vast majority of evidence demonstrates significant reductions in mortality and morbidity

Ivermectin, which since 1987 world time 3.7 billion used was, has made great strides in combating two devastating tropical diseases, onchocerciasis (river blindness) and lymphatic filariasis achieved. That is why ivermectin is widespread in Africa and in the countries where it is used, Covid is also completely inconspicuous as reported here.

In the year IVM treatment was first used for COVID-19, results from more than 20 randomized clinical trials (RCTs) of IVM treatment for COVID-19 were reported, with inpatient and outpatient treatments for COVID-19. 19 were carried out in 25 countries.

A likely biological mechanism is competitive binding to SARS-CoV-2 spike protein sites. A significant decrease in morbidity from IVM was also observed in two animal models, namely SARS-CoV-2 and a related beta coronavirus. The stated biological mechanism of IVM, competitive binding to the SARS-CoV-2 spike protein, is likely, not epitope-specific, possibly leading to full effectiveness against emerging viral mutant strains.

The events in Peru

During the massive IVM treatments in Peru, deaths in the ten states with the most extensive treatments decreased by an average of 74% in 30 days. The decrease in deaths correlated with the extent of IVM distribution in all 25 states.

In ten Peruvian states, massive IVM treatments for COVID-19 were carried out as part of the army-led Mega-Operación Tayta (MOT), which began at a different time in each state. In these states, deaths decreased by an average of 74% in 30 days, closely related to the onset of MOT.

In 14 Peruvian states where IVM was administered locally, the number of deaths fell by an average of 53% in 30 days, while in Lima, where very few IVMs were distributed during the first wave of the pandemic due to restrictive government policies, the number of Deaths within 30 days fell by 25%.

However, after a restrictive IVM treatment policy was put in place under the new Peruvian president, who took office on November 17, deaths rose 13-fold in the two months following December 1 through February 1, 2021.

Incidentally, something similar could be observed in India. The rise in case numbers and mortality coincides with a campaign against ivermectin. Only when the scientific associations such as the All India Institute of Medical Sciences (AIIMS) prevailed again, there was another decline. Without the suspension of ivermectin treatment, the already moderate increase with the Delta variant would not have been noticed.